Medical device company DexCom (NASDAQ: DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 19% above analysts’ consensus estimates.

Is now the time to buy DXCM? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not on insulin. Management highlighted progress in commercial coverage for this group, with expanded access helping to offset a slower pace of new patient starts in the U.S. While the company posted results above Wall Street’s expectations on both revenue and profit, the market responded negatively, reflecting concerns about U.S. market growth moderation. CEO Jake Leach acknowledged that while demand remains strong, “there is still a long runway to go” given only about one-third of covered lives are currently using continuous glucose monitoring (CGM) technology.

Looking ahead, DexCom’s outlook is anchored by ongoing efforts to unlock broader coverage, including potential Medicare expansion for type 2 non-insulin users and international reimbursement gains. Management is focused on converting existing patients to the new G7 15-day sensor, launching redesigned software like Stello, and advancing clinical evidence to support broader payer adoption. CFO Jereme Sylvain cited the upcoming randomized controlled trial (RCT) readout as a potential catalyst, stating, “Our expectation is to continue to unlock that coverage and help drive the growth algorithm,” while also noting the impact of cost controls and operational efficiency on margin guidance.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to broader U.S. access for type 2 patients, the G7 15-day launch, and operational improvements, but flagged that U.S. growth rates are moderating as coverage expansion slows.

• Type 2 non-insulin expansion: DexCom’s recent wins in commercial coverage for people with type 2 diabetes not on insulin have led to share gains in this segment, especially as Prime Therapeutics prepares to cover all people with diabetes this summer. Management emphasized that over 7 million non-insulin users are expected to have commercial coverage by year-end, and this group is a major focus for future growth.

• G7 15-day sensor rollout: The U.S. launch of the G7 15-day system, featuring extended wear and improved sensor accuracy, received positive feedback from both customers and physicians. CEO Jake Leach noted that nearly half of the active user base is expected to convert to the new sensor by year-end, supporting both new patient starts and retention.

• Operational efficiency and margin improvement: Gross margin improved year over year due to manufacturing efficiencies, normalized freight costs, and favorable initial uptake of the G7 15-day product. CFO Jereme Sylvain cited disciplined cost management, but cautioned that fuel and resin inflation could pose a 50–100 basis point headwind to gross margin for the remainder of the year.

• International growth through access wins: International revenue grew at a faster rate than the U.S., with particular strength in markets where DexCom secured new reimbursement or tender wins (such as France and Canada). Management highlighted that dual formulary wins and expanded product offerings are helping DexCom gain share in international tenders.

• Advances in product and digital ecosystem: Alongside hardware improvements, DexCom is redesigning its Stello app to include AI-driven personalized insights and enhanced nutrition tracking, aiming to improve user engagement and retention while broadening market reach through software innovation.

Drivers of Future Performance

DexCom’s guidance for the rest of the year centers on expanding payer coverage, product upgrades, and operational discipline, while navigating potential margin headwinds from input costs.

• Coverage unlock potential: Management believes that gaining Medicare coverage for type 2 non-insulin users remains a key growth driver, with the upcoming RCT results at the ADA conference expected to strengthen DexCom’s case with both U.S. and international payers. CEO Jake Leach noted, “It is really just a matter of time” before broader coverage is granted.

• Product adoption and ecosystem engagement: The ongoing conversion to the G7 15-day sensor, the rollout of new adhesive technology, and the redesigned Stello app are intended to boost new patient starts, improve retention, and provide deeper engagement, especially among primary care-managed populations and in international markets.

• Margin discipline amid external risks: CFO Jereme Sylvain indicated that while cost controls and manufacturing efficiencies are supporting margin expansion, uncertainties around oil, fuel, and resin prices could impact gross margin guidance. DexCom is maintaining a flexible approach to capital allocation, emphasizing investment in innovation and international expansion.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will be monitoring (1) the results and payer impact of the type 2 non-insulin RCT at the ADA Scientific Sessions, (2) the pace and scale of G7 15-day sensor adoption in both U.S. and international markets, and (3) additional commercial and Medicare coverage expansions for type 2 diabetes patients. Execution on digital ecosystem enhancements and progress in international tenders will also be critical to DexCom’s growth trajectory.

DexCom currently trades at $57.63, down from $59.75 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.